Phase 2 Completed N=120 Randomized Double-blind Treatment

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Bacterial Infections

Source: ClinicalTrials.gov NCT02269319 ↗

Enrolled (actual)

120

Serious AEs

0.8%

Results posted

Nov 2024

Primary outcomePrimary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants

Summary

The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline	72; 35	—
SECONDARY Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline	70; 32	—

Eligibility Criteria

Inclusion Criteria

Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI)
Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

Exclusion Criteria

Uncomplicated skin infections
Severe sepsis or septic shock
ABSSSI solely due to gram-negative pathogens
Prior systemic antibiotics within 96 hours of randomization

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02269319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.